title: [Clinical value of forced expiratory volume in 1 s (FEV1) in chronic obstructive pulmonary disease].
abstract: There is overwhelming evidence from large-scale placebo-controlled trials but also from epidemiologic COPD (chronic obstructive pulmonary disease) studies and meta-analyses supporting FEV(1) (forced expiratory volume in 1 s) as a strong diagnostic and prognostic marker that predicts future morbidity and mortality. Specifically, attenuation of reduced FEV(1) is a powerful indicator of successful medical intervention and vice versa. FEV(1) decline indicates an increasing risk for advanced disease stage eventually leading to further deterioration. However, it remains to be determined whether reducing the frequency of exacerbations or pharmacological improvement of FEV(1) can help to slow lung function decline and consequently improve clinical outcome in these patients. All in all, FEV(1) and its change over time are essential parameters in the assessment of COPD progression and efficacy of therapeutic intervention.
authors.affiliation: Robert-Koch-Klinik, Thoraxzentrum des Klinikums St. Georg, Leipzig, Germany. adrian.gillissen@sanktgeorg.de
authors.forename: Adrian
authors.initials: A
authors.lastname: Gillissen
authors.forename: Thomas
authors.initials: T
authors.lastname: Glaab
authors.forename: Roland
authors.initials: R
authors.lastname: Buhl
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011379:Prognosis; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012907:Smoking / Q000009:adverse effects; D016019:Survival Analysis; D016896:Treatment Outcome